- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 211/52 - Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
Patent holdings for IPC class C07D 211/52
Total number of patents in this class: 96
10-year publication summary
|
7
|
9
|
6
|
3
|
6
|
7
|
5
|
5
|
4
|
2
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4898 |
9 |
| Prilenia Neurotherapeutics Ltd. | 88 |
7 |
| Vertex Pharmaceuticals Incorporated | 1597 |
4 |
| AstraZeneca AB | 2909 |
2 |
| AstraZeneca UK Limited | 642 |
2 |
| Boehringer Ingelheim International GmbH | 4650 |
2 |
| Centre National de La Recherche Scientifique | 10418 |
2 |
| Agios Pharmaceuticals, Inc | 216 |
2 |
| Biophytis | 34 |
2 |
| Chugai Seiyaku Kabushiki Kaisha | 1355 |
2 |
| Nankai University | 234 |
2 |
| Nippon Soda Co., Ltd. | 895 |
2 |
| Novira Therapeutics, Inc. | 32 |
2 |
| Ono Pharmaceutical Co., Ltd. | 434 |
2 |
| Sentinel Oncology Limited | 38 |
2 |
| Sorbonne Universite | 1279 |
2 |
| Pharmaengine, Inc. | 11 |
2 |
| Mebias Discovery, Inc. | 8 |
2 |
| Janssen Pharmaceutica N.V. | 3392 |
1 |
| Board of Regents, The University of Texas System | 5793 |
1 |
| Other owners | 44 |